Short Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Expands By 28.4%

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the target of a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 3,530,000 shares, an increase of 28.4% from the January 31st total of 2,750,000 shares. Based on an average daily trading volume, of 1,330,000 shares, the days-to-cover ratio is presently 2.7 days. Currently, 4.4% of the company’s stock are short sold.

Hedge Funds Weigh In On Compass Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Rovin Capital UT ADV bought a new stake in shares of Compass Therapeutics during the third quarter valued at approximately $25,000. Tower Research Capital LLC TRC raised its stake in shares of Compass Therapeutics by 298.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock worth $25,000 after purchasing an additional 12,917 shares during the last quarter. Independent Advisor Alliance bought a new position in shares of Compass Therapeutics in the fourth quarter valued at approximately $26,000. BNP Paribas Financial Markets purchased a new position in shares of Compass Therapeutics during the fourth quarter valued at approximately $27,000. Finally, Intech Investment Management LLC bought a new stake in Compass Therapeutics during the third quarter worth $30,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Analyst Ratings Changes

CMPX has been the topic of a number of recent analyst reports. Jefferies Financial Group boosted their target price on Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, February 10th. Leerink Partners cut Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $5.00 to $4.00 in a report on Friday, November 15th. D. Boral Capital reissued a “buy” rating and set a $32.00 target price on shares of Compass Therapeutics in a report on Tuesday, February 25th. Piper Sandler started coverage on shares of Compass Therapeutics in a research report on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 target price for the company. Finally, Leerink Partnrs lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $11.38.

Compass Therapeutics Stock Down 1.3 %

CMPX traded down $0.04 during midday trading on Wednesday, hitting $2.75. 512,231 shares of the company were exchanged, compared to its average volume of 642,536. The firm’s 50 day moving average price is $2.64 and its 200-day moving average price is $1.98. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $4.08. The firm has a market capitalization of $377.68 million, a P/E ratio of -7.42 and a beta of 1.17.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). On average, sell-side analysts predict that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.